Spire Healthcare Group (LON:SPI) Receives “Overweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of Spire Healthcare Group (LON:SPI) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. They currently have a GBX 344 ($4.28) price objective on the stock.

Separately, Berenberg Bank upped their price objective on Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the stock a buy rating in a research note on Wednesday.

Spire Healthcare Group Trading Up 0.4 %

LON:SPI opened at GBX 249 ($3.10) on Thursday. The company has a debt-to-equity ratio of 170.37, a current ratio of 0.69 and a quick ratio of 0.74. The firm has a market capitalization of £1.01 billion, a price-to-earnings ratio of 3,542.86, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a one year low of GBX 204 ($2.54) and a one year high of GBX 321.71 ($4.00). The business has a fifty day moving average price of GBX 237.57 and a 200-day moving average price of GBX 228.97.

Spire Healthcare Group Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be paid a GBX 2.10 ($0.03) dividend. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, May 23rd. This is a positive change from Spire Healthcare Group’s previous dividend of $0.50. Spire Healthcare Group’s dividend payout ratio is presently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.